WELL Health: A Growth Stock to Consider for Your Portfolio

If you are looking to invest in undervalued growth stocks, WELL Health is a top bet right now.

| More on:

In the last decade, growth stocks have been on an absolute tear and have crushed the broader markets by a huge margin. Growth stocks remain an enticing bet for long-term investors, as these companies are able to grow revenue and profit margins at a rapid pace, thereby generating exponential returns over time.

One such growth stock on the TSX is WELL Health Technologies (TSX:WELL), a company that I have extensively covered in the last week. Right now, this digital health stock is trading at an attractive valuation and has significant upside potential given recent developments.

WELL Health is at the top of my radar again, as the company disclosed it is the first Canadian EMR (electronic medical record) and telehealth platform to offer Apple Health Records in Canada.

This means that anyone with an iPhone already has the app (it comes factory installed on every phone), which can retrieve health records from participating clinics. WELL Health set out to modernize healthcare, and this is more proof that they are making this happen. This collaboration with Apple is likely just the beginning of what is coming.

The company’s chairman and CEO Hamed Shahbazi said, “We are delighted to be the first telehealth and Canadian EMR platform in Canada to offer health records and enable patients to download and view their health information on iPhone. Providing patients with an easy and convenient method to get access to their available health records right on their iPhone can help them more actively participate in their health, leading to better health outcomes and a higher patient understanding of their own overall health status.”

I believe WELL has what it takes to remain a top bet for 2021 and beyond.

Focus on acquisitions

WELL Health is a company that has grown via accretive acquisitions over the years. Last month, it completed the acquisition of Intrahealth, which is an enterprise-class EMR provider with a global network of healthcare customers in Australia, Canada, and New Zealand.

In March, WELL Health disclosed it made an early-stage seed investment in Twig Fertility which is a start-up fertility clinic. In order to acquire CRH Medical, WELL Health completed an equity offering totaling over $300 million, which was led by noted Hong Kong investor Li Ka-Shing and several other institutions.

In January, WELL Health acquired Open Health Software Solutions, which is an OSCAR service provider to medical clinics in Ontario. It also acquired Adracare, which is an omnichannel practice management platform that serves 6,800 allied healthcare practitioners in five countries.

Last year, WELL expanded to Quebec after it acquired ExcelleMD, a healthcare entity that provides in-person and virtual care services via its five multi-disciplinary clinics.

WELL Health is trading at an attractive valuation

Driven by its slew of acquisitions, WELL Health is forecast to increase sales by a stellar 353% to $227.6 million in 2021. Further, analysts expect sales to increase by 43% to $325 million in 2022. While it posted an adjusted loss in 2020, WELL Health is expected to report earnings of $0.01 per share this year and $0.08 in 2022.

It means, WELL stock is trading at a forward price-to-sales multiple of less than six, which is very reasonable for a high-growth company.

Bay Street believes WELL Health stock is undervalued and has a 12-month average target price of $11.56, which is 68% above its current trading price.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

David Gardner owns shares of Apple. The Motley Fool owns shares of and recommends Apple and recommends the following options: short March 2023 $130 calls on Apple and long March 2023 $120 calls on Apple. Fool contributor Aditya Raghunath has no position in any of the stocks mentioned.

More on Investing

Blocks conceptualizing Canada's Tax Free Savings Account
Dividend Stocks

How to Use Your TFSA to Double Your TFSA Contribution

If you're looking to double up that TFSA contribution, there is one dividend stock I would certainly look to in…

Read more »

Income and growth financial chart
Investing

A Top-Performing U.S. Stock That Canadian Investors Really Should Own

Amazon (NASDAQ:AMZN) is starting to run faster in the AI race, making it a top U.S. pick for 2025.

Read more »

Person uses a tablet in a blurred warehouse as background
Tech Stocks

2 Canadian AI Stocks Poised for Significant Gains

Here are two top AI stocks long-term investors may want to consider before the end of the year.

Read more »

man touches brain to show a good idea
Investing

3 No Brainer Tech Stocks to Buy With $500 Right Now

Here are three no-brainer tech stocks long-term investors on a limited budget may want to consider right now.

Read more »

woman looks at iPhone
Dividend Stocks

Retirees: Is TELUS Stock a Risky Buy?

TELUS stock has long been a strong dividend provider, but what should investors consider now after recent earnings?

Read more »

Concept of multiple streams of income
Dividend Stocks

Is goeasy Stock Still Worth Buying for Growth Potential?

goeasy offers a powerful combination of growth and dividend-based return potential, but it might be less promising for growth alone.

Read more »

A person looks at data on a screen
Dividend Stocks

How to Use Your TFSA to Earn $300 in Monthly Tax-Free Passive Income

If you want monthly passive income, look for a dividend stock that's going to have one solid long-term outlook like…

Read more »

Man holds Canadian dollars in differing amounts
Investing

Is Dollarama Stock a Buy?

Although Dollarama's stock is expensive and has rallied by more than 40% over the last year, is it still worth…

Read more »